Welcome to our dedicated page for Equillium SEC filings (Ticker: EQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.
Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.
Equillium, Inc. senior vice president and COO Christine Zedelmayer reported an exercise-and-sell set of transactions in company common stock. On February 19, 2026, she exercised options to acquire a total of 185,937 shares of common stock at prices of $0.785 and $0.73 per share.
On the same date, she sold the same 185,937 shares in open-market transactions at average prices of about $1.78 per share. After these trades, she directly held 91,444 shares of Equillium common stock. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025, indicating they were pre-arranged rather than timed discretionarily.
Equillium, Inc. senior vice president and COO Christine Zedelmayer exercised stock options and sold shares in a planned transaction. On March 9, 2026 she exercised options for a total of 152,361 shares of common stock at an exercise price of $0.785 per share.
The same day she sold 181,219 shares of common stock at a weighted average price of $2.00 per share, with individual sale prices ranging from $2.00 to $2.015, under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions she directly owned 62,586 shares of Equillium common stock.
Christine Zedelmayer reported sales of common stock under Rule 144. The filing lists four transactions dated 11/25/2025, 12/12/2025, 12/15/2025, and 02/19/2026 totaling 229,739 shares sold for aggregate proceeds of $377,658.
The transactions are reported on Form 144 and reflect dispositions from stock option-related and employee plan holdings referenced in the securities table.
Equillium, Inc. executive Christine Zedelmayer reported option exercises and related share sales in a Form 4. On February 19, 2026, she exercised employee stock options covering 109,375 and 76,562 shares, converting them into common stock at stated exercise prices.
On the same date, she sold 109,375 shares at $1.7814 per share and 76,562 shares at $1.7406 per share in open-market transactions. The filing states these sales were made under a Rule 10b5-1 trading plan adopted on August 27, 2025. After these transactions, she directly owned 191,444 shares of Equillium common stock.
EQ reported insider sales via Form 144 by Christine Zedelmayer. The filing lists multiple reported dispositions of Common Stock on 11/25/2025 (8,098 shares, $7,696.00), 12/12/2025 (23,804 shares, $31,897.00), 12/15/2025 (11,900 shares, $15,589.00), and 12/23/2025 (100,000 shares, $150,000.00).
The filing also lists planned sales of Common Stock issuable upon exercise of stock options dated 01/12/2022 (109,375 shares) and 01/02/2024 (76,562 shares), with sale method indicated as Cash.
Janus Henderson Group plc has filed an amended Schedule 13G reporting beneficial ownership of 6,083,239 shares of Equillium, Inc. common stock, representing 9.99% of the class. These holdings are managed through various affiliated asset managers on behalf of client accounts, called Managed Portfolios.
The position includes shares that may be obtained through exercise of certain pre-funded warrants that are exercisable within 60 days, but only to the extent total beneficial ownership does not exceed 9.99% of Equillium’s outstanding common stock. An additional 18,584,856 warrants are excluded from the reported figures due to this ownership cap. Dividends and sale proceeds belong to the Managed Portfolios, not Janus Henderson.
Equillium, Inc. granted its President and Chief Scientific Officer, Stephen Connelly, an employee stock option to buy 1,150,000 shares of common stock at an exercise price of $1.31 per share on 01/07/2026. The option has an expiration date of 01/06/2036 and was received at no cost, as reflected by a derivative security price of $0.
According to the vesting terms, 25% of the shares under the option vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Connelly beneficially holds 1,150,000 stock options directly.
Equillium, Inc. reported that Sr. Vice President and COO Christine Zedelmayer received an employee stock option grant on 01/07/2026. The derivative award covers 500,000 stock options with an exercise price of $1.31 per share, allowing her to buy common stock at that price in the future. The grant was reported at a cost of $0 for the option itself and leaves her with 500,000 derivative securities beneficially owned directly after the transaction.
According to the vesting terms, 25% of the option vests on the first anniversary of the vesting commencement date, and the remaining options vest in 36 equal monthly installments over the following three years, resulting in a standard four-year vesting schedule tied to ongoing service.
Equillium, Inc. reported that its Chief Executive Officer, director and 10% owner, Bruce D. Steel, was granted an employee stock option on 01/07/2026. The option covers 1,750,000 shares of common stock at an exercise price of $1.31 per share and expires on 01/06/2036. According to the vesting terms, 25% of the shares vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, Steel beneficially holds 1,750,000 derivative securities directly.
Equillium, Inc. Principal Accounting Officer Tom Penny reported one stock sale and a new stock option grant. Penny sold 6,533 shares of common stock on January 8, 2026 at $1.29 per share, leaving him with no shares of common stock held directly after the sale. The filing notes these sales were made under a Rule 10b5-1 trading plan adopted on October 10, 2025, meaning they were pre‑scheduled rather than discretionary.
On January 7, 2026, Penny was granted an employee stock option to purchase 450,000 shares of Equillium common stock at an exercise price of $1.31 per share. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining shares vesting in 36 equal monthly installments over the following three years. After this grant, he holds 450,000 stock options directly.